Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
European Journal of Cancer (Oxford, England : 1990)|April 26, 2023
Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitorsPaolo Manca, Francesca Corti, Rossana Intini, et al.
British Journal of Cancer|February 12, 2024
HER2 expression and genOmic characterization of rESected brain metastases from colorectal cancer: the HEROES studyAlessandra Anna Prete, Valentina Angerilli, Francesca Bergamo, et al.
European Journal of Cancer (Oxford, England : 1990)|April 26, 2021
The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitorsFrancesca Corti, Sara Lonardi, Rossana Intini, et al.
JCO Precision Oncology|November 7, 2024
KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted AlterationRoberto Moretto, Daniele Rossini, Sabina Murgioni, et al.
Therapeutic Advances in Medical Oncology|January 8, 2025
Prognostic impact of depth of response and early tumour shrinkage in patients with BRAF -mutated metastatic colorectal cancer treated with targeted therapyGuglielmo Vetere, Marco Maria Germani, Carlotta Antoniotti, et al.
European Journal of Cancer (Oxford, England : 1990)|December 21, 2021
Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancerGiovanni Randon, Rossana Intini, Chiara Cremolini, et al.
Journal for Immunotherapy of Cancer|January 2, 2023
Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancerVincenzo Nasca, Francesco Barretta, Francesca Corti, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2025
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studiesR Moretto, D Rossini, Mariam Grazia Polito, et al.
Clinical Colorectal Cancer|September 1, 2023
Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal OriginFilippo Ghelardi, Alessandra Raimondi, Federica Morano, et al.
Journal for Immunotherapy of Cancer|August 25, 2021
Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitorsFilippo Pietrantonio, Sara Lonardi, Francesca Corti, et al.
Pageof 4